期刊文献+

270株鲍曼不动杆菌耐药性分析 被引量:6

Analysis on the Drug Resistance of 270 Strains of Baumanii
下载PDF
导出
摘要 目的:了解鲍曼不动杆菌的耐药性,为临床合理选用抗菌药物提供参考。方法:对我院2001年-2004年从临床标本分离 出的270株鲍曼不动杆菌的药敏试验结果进行统计分析。结果:鲍曼不动杆菌检出率为16.6%,对哌拉西林/他唑巴坦无耐药菌株 产生;对亚胺培南和氨苄西林/舒巴坦的耐药率分别为16.3%、22.6%;对阿莫西林/克拉维酸的耐药率为33.3%;对其它抗菌药物 均有较高的耐药率,以头孢菌素类尤甚。结论:加强对鲍曼不动杆菌的耐药性监测,规范抗菌药物的应用,对保持敏感抗菌药物的抗 菌活性具有重要意义。 OBJECTIVE: To study the drug resistance of baumanii so as to provide references for rational use of antibiotics in the clinic. METHODS: The susceptibility test results of 270 strains of baumanii isolated from clinical samples in our hospital during the period of 2001-2004 were analyzed statistically. RESULTS: The isolating rate of baumnii stood at 16.6%, which had no drug resistance strains to piperacillin/tazobactam; its drug resistance rates to lmipenem and ampicillin/sulbactam stood at 16.a% and 22.6%, respectively; its drug resistance rates to amoxicillin/clavulanic acid stood at 33.3%; which had higher drug resistance rates to the other antibacterials, particularly to cephalosporins. CONCLUSIONS: To reinforce the monitoring on the drug resistance of baumanii and to standardize the application of antibacterials are helpful for the maintaining of antibacterial activity of sensitive antibacterials.
出处 《中国药房》 CAS CSCD 北大核心 2005年第21期1647-1648,共2页 China Pharmacy
关键词 鲍曼不动杆菌 抗菌药物 耐药性 Baumanii Antibacterials Drug resistance
  • 相关文献

参考文献6

二级参考文献26

  • 1于秀娟,姚苹,孔庆莲.呼吸系统不动杆菌感染的多重耐药性与耐药基因的检测[J].中华医院感染学杂志,2004,14(4):369-372. 被引量:16
  • 2Karlowsky JA, Deborahc,et al. Surveillance for antlmicrobial susceptibility among clinical isolates of Pseudomonas aerugi-nosa and Acinetobacter baumannii from hospitalized patients in the United States,1998 to 2001 [J]. Antimictob AgentsChemother, 2003, 47(5): 1681-1688.
  • 3Hsueh PR , Teng LJ , Chen CY , et al . Pandrug resistant Acinetobacter baumannii causing nosocomial infections in a uni-versity hospital, Taiwan[J]. Emerg Infect Dis, 2002, 8(8):827-832.
  • 4National Committee for Clinical Laboratory Standards. Perfor-mance standards for antimicrobial susceptibility testing [S].Approved Standard M100-S12. NCCLS, 2002.
  • 5Poirel L, Menuteau O, et al. Outbreak of extended spectrum β lactamase VEB-1 producing isolates of Acinetobacter bauman-nil in a French hospital[J]. J Clin Microbiol, 2003, 41 (8):3542-3547.
  • 6Ribera A, Ruiz J, Vila J. Presence of the Tet M determinant in a clinical isolate of Acinetobacter baumannii[J]. Antimicrob Agents Chemothtr, 2003, 47(7): 2310-2312.
  • 7Jean SS, Teng LT, Hsueh PR, et al. Antimicrobial suscepti-bility among clinical isolates of extended spectrum cephalosporin resistant Gram negative bacteria in a Taiwan Residents university hospital [J]. J Antimicrob Chemother, 2002, 49(1): 69-76.
  • 8Hsueh PR. Liu YC, Yang D, et al. Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in in-tensive care units in 2000 in Taiwan[J]. Microb Drug Resist,2001,7(4) :373-382.
  • 9Henwood C J, Gatword T, Warner M, et al. Antibiotic resis-tance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecyclin[J]. J Antimicrob Chemother.2002. 49(3): 479-487.
  • 10Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment [J].Clin Microbiol Infect, 2002,8 (11): 687.

共引文献226

同被引文献23

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部